

## Article

# Acceptability and Feasibility of a 13-Week Pilot Randomised Controlled Trial Testing the Effects of Incremental Doses of Beetroot Juice in Overweight and Obese Older Adults

Abrar M Babateen <sup>1,2</sup>, Oliver M Shannon <sup>1</sup>, Gerard M O'Brien <sup>1</sup>, Edward Okello <sup>1,3</sup>, Anmar A Khan <sup>2</sup>, Sofia Rubele <sup>4</sup>, Emma Wightman <sup>5,6</sup>, Ellen Smith <sup>5,6</sup>, Nicholas McMahon <sup>7</sup>, Dilara Olgacer <sup>1</sup>, Christina Koehl <sup>1</sup>, William Fostier <sup>1</sup>, Inês Mendes <sup>8</sup>, David Kennedy <sup>5,6</sup>, John C Mathers <sup>1</sup> and Mario Siervo <sup>9,\*</sup>

**Citation:** Babateen, A.M.; Shannon, O.M.; O'Brien, G.; Okello, E.; Khan, A.A.; Rubele, S.; Wightman, E.; Smith, E.; McMahon, N.; Olgacer, D.; et al. Acceptability and Feasibility of a 13-Week Pilot Randomised Controlled Trial Testing the Effects of Incremental Doses of BEETROOT juice in Overweight and Obese Older Adults. *Nutrients* **2021**, *13*, 769. <https://doi.org/10.3390/nu13030769>

Academic Editor: Antoni Sureda

Received: 24 January 2021

Accepted: 22 February 2021

Published: 26 February 2021

Academic Editor: Antoni Sureda

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the author. Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

<sup>1</sup> Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK; A.m.o.babateen2@ncl.ac.uk (A.M.B.); oliver.shannon@ncl.ac.uk (O.M.S.); gerard.o'brien@newcastle.ac.uk (G.M.O.); edward.okello@newcastle.ac.uk (E.O.); olgacerdilara@gmail.com (D.O.); chrissi.koehl18@gmail.com (C.K.); W.fostier@ncl.ac.uk (W.F.); john.mathers@ncl.ac.uk (J.C.M.)

<sup>2</sup> Faculty of Applied Medical Sciences, Clinical Nutrition Department, Umm Al-Qura University, Makkah 21421, Saudi Arabia; aaakhan@uqu.edu.sa

<sup>3</sup> Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne NE1 7RU, UK

<sup>4</sup> Department of Geriatrics, St Bortolo Hospital, Vicenza, 37030 Verona, Italy; sofiarubele89@hotmail.it

<sup>5</sup> Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK; emma.l.wightman@northumbria.ac.uk (E.W.); ellen.smith@northumbria.ac.uk (E.S.); david.kennedy@northumbria.ac.uk (D.K.).

<sup>6</sup> Nutrition Trials at Northumbria (NUTRAN), Northumbria University, Newcastle Upon Tyne NE1 8ST, UK

<sup>7</sup> School of Human Movement and Nutrition Sciences, University of Queensland, St. Lucia, QLD 4067, Australia; n.mcmahon2@uq.edu.au

<sup>8</sup> Endocrinology and Nutrition Department, Divino Espirito Santo Hospital, D.Manuel I Avenue, 9500-370 Azores, Portugal; ines\_c\_mendes@hotmail.com

<sup>9</sup> School of Life Sciences, Queen's Medical Centre, The University of Nottingham Medical School, Nottingham NG7 2UH, UK

\* Correspondence: mario.siervo@nottingham.ac.uk; Tel.: +44-(0)115-8230279

**Abstract:** Nitrate-rich food can increase nitric oxide production and improve vascular and brain functions. This study examines the feasibility of a randomised controlled trial (RCT) testing the effects of prolonged consumption of different doses of dietary nitrate (NO<sub>3</sub><sup>-</sup>) in the form of beetroot juice (BJ) in overweight and obese older participants. A single-blind, four-arm parallel pilot RCT was conducted in 62 overweight and obese (30.4 ± 4 kg/m<sup>2</sup>) older participants (mean ± standard deviation (SD), 66 ± 4 years). Participants were randomized to: (1) high-NO<sub>3</sub><sup>-</sup> (HN: 2 × 70 mL BJ/day) (2) medium-NO<sub>3</sub><sup>-</sup> (MN: 70 mL BJ/day), (3) low-NO<sub>3</sub><sup>-</sup> (LN: 70 mL BJ on alternate days) or (4) Placebo (PL: 70 mL of NO<sub>3</sub><sup>-</sup>-depleted BJ on alternate days), for 13 weeks. Compliance was checked by a daily log of consumed BJ, NO<sub>3</sub><sup>-</sup> intake, and by measuring NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> concentrations in plasma, saliva, and urine samples. Fifty participants completed the study. Self-reported compliance to the interventions was >90%. There were significant positive linear relationships between NO<sub>3</sub><sup>-</sup> dose and the increase in plasma and urinary NO<sub>3</sub><sup>-</sup> concentration (R<sup>2</sup> = 0.71, P < 0.001 and R<sup>2</sup> = 0.46 P < 0.001, respectively), but relationships between NO<sub>3</sub><sup>-</sup> dose and changes in salivary NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> were non-linear (R<sup>2</sup> = 0.35, P = 0.002 and R<sup>2</sup> = 0.23, P = 0.007, respectively). The results confirm the feasibility of prolonged BJ supplementation in older overweight and obese adults.

**Keywords:** dietary nitrate; older adults; overweight/obese

## 1. Introduction

Increased life expectancy is associated with a concomitant rise in the occurrence of age-related medical conditions, including cardiovascular, metabolic and neurological diseases [1]. In the UK, the number of individuals aged 60 years and over is expected to increase by 8.6 million over the next five decades [2]. Therefore, it is of paramount importance to promote and protect the quality of life of older people through developing primary preventive interventions. Since diet has a major influence on ageing and on the risk of age-related diseases [3], the identification of nutritional and lifestyle factors associated with healthy ageing is a priority. However, conducting nutritional intervention studies in older populations is often challenging.

Recruitment of older participants in clinical research studies can be demanding [4]. Older participants are more likely to be excluded from studies due to pre-existing medical conditions, such as limited mobility, polypharmacy or the presence of chronic diseases [5]. Hence, recruitment may become a more difficult and time-consuming process despite the fact that older participants are often more willing to participate in clinical trials compared with younger participants [6]. In addition, given the medical complexities associated with ageing, attrition rates from studies may be increased, which is another concern from the researcher's perspective [7]. Compliance with dietary interventions or study protocols may be difficult for older people. The potential for adverse events could also affect compliance as well as difficulties around high frequency of intake, rigid conditions for ingestion times, and onerous preparation of meals in study protocols [8]. Although some strategies to address reasons for non-participation in clinical research and to improve compliance with study protocols have been proposed [7,9,10], there is considerable need for improved design and performance of intervention studies in older people. This gap can be addressed through sharing of experiences, challenges and successes in recruiting and retaining older adults in nutritional intervention studies and related clinical research.

This pilot randomised controlled trial (RCT) was designed to determine the feasibility and acceptability of the protocol for a 13-week intervention study in which overweight and obese older participants were asked to consume different doses of  $\text{NO}_3^-$  rich beetroot juice (BJ). Ageing and obesity are associated with reduced NO availability due to several factors including increased oxidative stress, decreased activity of endothelial NO synthase and also increased production of endogenous NO inhibitors such as asymmetric dimethyl arginine (ADMA) [11]. Thus, supplemental  $\text{NO}_3^-$  may be more effective in older, obese individuals than in healthy younger people. Whilst a number of studies have investigated the effects of BJ in older adults [12–14], these studies have been characterised by short duration which may pose fewer issues with compliance than longer-term studies. To our knowledge, the present 13-week study is one of the longest RCTs that has tested the effect of different BJ doses in older overweight and obese participants.

## 2. Materials and Methods

### 2.1. Ethical Approval

The study was approved by the Faculty of Medical Sciences, Newcastle University (1503/4477/2018). The intervention study was registered with the ISRCTN registry (International Standard Randomised Controlled Trial Number) (ISRCTN14746723).

### 2.2. Participants and Study Design

This was a randomised, single-blind, placebo-controlled, four-arm parallel feasibility trial. All recruited participants were older (60 to 75 years), overweight or obese (body mass index (BMI) range: 25–40  $\text{kg}/\text{m}^2$ ) adults. Participants were recruited from members of staff or the general public who responded to our newspaper or social media advertisements, flyers or emails between July 2018 and April 2019. Eligible participants were screened to confirm their eligibility and written informed consent was obtained subsequently from them before entering the study. Participants were randomised to one of four

treatments that were administered for 13 weeks. The treatments were: (1) High Nitrate (HN); two 70 mL shots of concentrated BJ per day (~400 mg of  $\text{NO}_3^-$  per shot), one in the morning (~8:00am) and one in the evening (~9:00pm). (2) Medium Nitrate (MN), one shot of concentrated BJ in the evening (~9:00pm). (3) Low Nitrate (LN), one shot of concentrated BJ every other evening (~9:00pm). (4) Placebo (PL), one shot of  $\text{NO}_3^-$  depleted BJ (~0.001 mg of  $\text{NO}_3^-$ ) every other evening (~9:00pm). The randomization pattern was generated using the RAND function in Excel (Excel Microsoft software, Version 16.46, Microsoft corp., Redmond, WA, USA). Further details on participants recruitment, selection, and screening have been described elsewhere [15].

### 2.3. Primary and Secondary Outcome Measures

The primary outcomes of the trial were measures of feasibility, acceptability, and compliance with the interventions and with the study protocol. Secondary outcomes included testing the effects of the different doses of dietary  $\text{NO}_3^-$  on measures of cognitive, vascular and pulmonary functions and on cerebral blood flow.

### 2.4. Data Collection Procedures

All data were collected over one year between July 2018 and July 2019. Baseline measurements were taken on two separate consecutive days, as some measurements were conducted in two different locations (Newcastle University and Northumbria University). Participants were asked to follow a 24-hour run-in diet to standardise their  $\text{NO}_3^-$  intake which included avoidance of green leafy vegetables and avoiding alcohol and caffeine consumption for 24 hours before both baseline visits. On the first day, participants arrived at the research facility in the morning (between 09:30–10:00) in a fasted condition (~12 h after the previous meal). Body composition, waist circumference and biological samples including blood, saliva and urine samples, as well as salivary strips, were collected. In addition, measurements of cognitive, vascular and pulmonary functions were performed. The measurement protocols have been described [15] and the results of the secondary outcome measures will be published in due course.

Participants returned the following day for the second baseline visit at Northumbria University between 15:00 and 16:00 to perform the cerebral blood flow measurement as described elsewhere [15]. Biological samples including salivary  $\text{NO}_2^-$  strips, saliva and urine samples were collected in the morning at home after an overnight fast (~12 h).

The end study visits were performed after 13 weeks following the same order as for the baseline measurements. These two visits were scheduled to occur ~12 h after the consumption of the last BJ dose for HN and MN groups, and ~36 hours after the consumption of the last BJ dose for the LN and PL groups.


Participants were asked to complete the short-version of the international physical activity questionnaire (IPAQ) [16] at home to estimate their physical activity over the week prior to the first baseline, the interim (6 weeks) and the end of the study (13 weeks). To assess dietary  $\text{NO}_3^-$  intake (excluding the intervention supplement) during the study, participants were asked to record their food intake every two weeks using an online 24-hour dietary recalls (Intake24; six dietary records were collected in total). Participants were instructed not to change their dietary habits or physical activity patterns and to avoid using mouthwash during the study as the latter has been shown to destroy oral bacteria involved in  $\text{NO}_3^-$  reduction in the body [17]. All participants were informed that reasonable travel expenses would be covered, and each participant received a £60 voucher at the end of the study.

### 2.5. Compliance

#### 2.5.1. Compliance with the Dietary Intervention

The assessment of participant compliance with the intervention has been described in detail elsewhere [15]. Briefly, compliance was checked primarily by completing a daily

log to record the time of BJ consumption, and also to report any BJ bottles that were not consumed. Compliance with the intervention was also assessed objectively by measuring  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations in plasma, saliva and urine samples and using salivary strips. The protocol for the collection of the biological samples is described in Figure 1.



**Figure 1.** Summary of the collection of biological samples during the study. Urine collection kit used is (Biological substance Category B, Shuttlepac, UK).

Blood samples were collected in the research centre at baseline and after 13 weeks (visit 1 and visit 4). Urine, saliva and salivary  $\text{NO}_2^-$  strips were collected at baseline, at 4 weeks (for 3 consecutive days), 8 weeks (for 3 consecutive days), and 13 weeks.

### 2.5.2. Compliance with the Study Protocol

Participants were requested to collect biological samples (urine and saliva), and salivary  $\text{NO}_2^-$  strips at home and to post them to the research centre using the national mail delivery service. In addition, participants were asked to report their dietary intake using Intake24 every 2 weeks.

### 2.6. Recording Food Intake Using Intake24

Intake24 is a user-friendly, interactive web-based tool based on 24-hour recall for the assessment of dietary intake [18], that was used to assess  $\text{NO}_3^-$  intake every two weeks during the study (6 entries in total for each participant). In this manuscript, the number of 24-hour records completed at each time point is reported.

### 2.7. Collection and Analysis of Biological Samples

Samples collection procedures have been described in detail elsewhere [15]. Briefly, blood samples were collected after an overnight fast (~12 h) at baseline and 13 weeks. The samples were processed within 10 min of collection to minimize  $\text{NO}_2^-$  degradation. Salivary  $\text{NO}_2^-$  strips, urine and saliva samples were collected at baseline (both visits) and then again at 4 weeks (3 consecutive days), 8 weeks (3 consecutive days), and 13 weeks of intervention (both visits) (see Figure 1). Blood and salivary samples were used to measure  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations, while urine samples were used to measure  $\text{NO}_3^-$  concentrations. Salivary strips (Berkeley Test strips, Berkeley life, Chicago, USA) were used to estimate salivary  $\text{NO}_2^-$  concentration and also to evaluate their utility as a measure of longer-term compliance to  $\text{NO}_3^-$  interventions.

Sample analysis was conducted using ozone-based chemiluminescence (Sievers NOA 280i, Analytix Ltd, Durham, UK), as previously described [19]. Salivary  $\text{NO}_2^-$  strips analysis was conducted as described [15]. A brief description of both methods is reported in the online supplementary material.

### 2.8. Acceptability with Intervention and Study Protocol

At the end of the study, participants completed a 25-item questionnaire to obtain feedback on the intervention and study protocol. The questionnaire took 10–15 minutes to complete. Questions were designed to obtain information on the following specific topics: (1) reasons for joining the study and expectation from the study, (2) the duration of the study, (3) nutritional supplementation and (4) measurement protocols. The questionnaire included a range of closed and open questions. Based on the participants' responses to the open questions, the answers were categorised into specific topics and the frequency of each response topic was calculated (See Supplementary Material).

### 2.9. Sample Size Calculation

This was a pilot study designed to assess the feasibility and acceptability of the proposed intervention. A sample size of 15 per intervention group was based on (i) the predicted effect size of the intervention on cognitive changes (Trail making test-B) [20] and (ii) the guidelines indicated by Whitehead et al., (2016) [21], who provided guidance on sample size calculation for pilot studies with the aim of maximising use of resources and avoiding type II errors. Specifically, a sample size of 15 individuals per group would provide a 90% power to detect a medium effect size between 0.3 and 0.7.

### 2.10. Data Presentation and Statistical Analysis

Continuous data are summarised as mean  $\pm$  standard deviation (SD) and categorical data are presented as percentage (%). Normality distribution of data was checked by visual inspections of histograms and by Shapiro-Wilks test. One-way analysis of variances (ANOVA) was used to compare baseline characteristics between intervention groups. Categorical variables were analysed by Chi-square test.

**Feasibility and compliance:** Feasibility of the intervention was evaluated by collating quantitative information on eligibility, recruitment and retention of participants in the trial. Retention was estimated by calculating the proportion of enrolled participants who dropped out and were lost to follow up. Intervention compliance rate was estimated as the proportion of BJ shots consumed relative to the total dispensed shots i.e., (number of BJ bottles consumed/total number of BJ required to be consumed during the 13 weeks)  $\times$  100. Participants were considered compliant if they reported consumption of 80% or more of their BJ during the 13 weeks of the study. Compliance with the intervention was also assessed by measuring changes in biomarkers of dietary NO<sub>3</sub><sup>-</sup> intake including plasma, urinary and salivary concentrations of NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup>. Compliance with other aspects of the study protocol including home collection of biological samples and posting the samples to the laboratory, and recording dietary intakes using Inake24 was evaluated.

**Biomarkers analysis:** Summary data are presented as mean  $\pm$  standard error of the mean (SEM) in figures, and 95% confidence intervals (CI) in the text. Only data from participants who completed the study were included in the analysis. A paired *t*-test was used to assess the between-day repeatability of biomarkers for the two visits conducted at baseline and also at the end of the study. To evaluate changes in biomarker concentrations post-supplementation, the mean value for both testing days (baseline and end of the study) was used in the analyses. Changes over time were analysed using two-factor repeated-measure ANOVA with time as a within-subjects factor and intervention as a between-subjects factor. Models were checked for sphericity assumptions and multivariate models were applied if assumptions were violated. If the model was significant, Dunnett's test was used to compare the effects of different doses of NO<sub>3</sub><sup>-</sup>. In addition, the change from baseline was calculated for each individual and then treatments were compared using one-way ANOVA. One-way ANOVA was also used to determine whether delays in the delivery of the samples collected at home affected salivary and urinary NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> concentrations (all interventions were combined together in this analysis). To investigate dose-response relationships between supplemental doses of NO<sub>3</sub><sup>-</sup> and concentrations of

NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> in biofluids, polynomial regression analysis was used. Associations between salivary NO<sub>2</sub><sup>-</sup> concentrations measured by chemiluminescence and the values obtained from salivary strips were investigated using Pearson's correlation analysis. Statistical significance was set at  $P < 0.05$ . All statistical analyses were completed using (IBM SPSS, version 23, New York, USA).

### 3. Results

#### 3.1. Baseline Characteristics

The baseline characteristics (summarised in Table 1) show that the participants in each intervention group were well-matched for anthropometric variables, age and blood pressure. The age of participants ranged from 60 to 73 years (mean  $\pm$  SD,  $66 \pm 4$ ) and 62% were men ( $n = 38$ ). Fifty-six percent of participants were overweight and the remaining 44% were obese. BMI ranged from 25 to 39 kg/m<sup>2</sup> ( $30.4 \pm 4$  kg/m<sup>2</sup>). Systolic blood pressure ranged from 110 to 167 mmHg ( $135 \pm 15$  mmHg) and diastolic blood pressure from 60 to 100 mmHg ( $77 \pm 10$  mmHg). Six participants were hypertensive and on antihypertensive medication and 27 participants were on other medications as reported in Table 1.

**Table 1.** Baseline characteristics of the study participants including use of medications.

	All	HN	MN	LN	PL	P-value
Characteristics						
Number	62	16	17	14	15	-
Gender, M/F	24/38	10/6	12/5	4/10	5/10	0.16
Age (years)	66.3 $\pm$ 3.7	64.7 $\pm$ 3.5	66.7 $\pm$ 4.2	67.3 $\pm$ 2.7	65.7 $\pm$ 3.9	0.16
Education (years)	15.3 $\pm$ 3.0	16.0 $\pm$ 3	15.7 $\pm$ 2.6	15.0 $\pm$ 3.1	14.6 $\pm$ 3.1	0.73
Body weight (kg)	84.9 $\pm$ 12.6	90.9 $\pm$ 13.4	84.6 $\pm$ 10.5	80.1 $\pm$ 12.5	83.9 $\pm$ 12.6	0.15
BMI (kg/m <sup>2</sup> )	30.3 $\pm$ 3.7	30.5 $\pm$ 3.6	30.5 $\pm$ 3.2	29.9 $\pm$ 3.4	30.3 $\pm$ 4.8	0.99
WC (cm)	102.4 $\pm$ 9.2	104.5 $\pm$ 10.3	100.6 $\pm$ 9.6	102.1 $\pm$ 8.9	102.6 $\pm$ 8.2	0.59
FM (kg)	32.4 $\pm$ 8.7	32.1 $\pm$ 8.7	34.5 $\pm$ 9.0	31.3 $\pm$ 7.2	31.5 $\pm$ 10.0	0.90
FM (%)	37.8 $\pm$ 7.8	35.2 $\pm$ 8.2	39.2 $\pm$ 7.8	39.3 $\pm$ 6.6	37.1 $\pm$ 8.1	0.41
TBW (kg)	38.6 $\pm$ 6.3	41.3 $\pm$ 7.4	38.6 $\pm$ 4.5	35.6 $\pm$ 6.3	38.8 $\pm$ 5.9	0.18
SBP (mm Hg)	135.1 $\pm$ 14.7	130.8 $\pm$ 12.0	136.1 $\pm$ 10.4	139.5 $\pm$ 13.2	134.1 $\pm$ 12.9	0.46
DBP (mm Hg)	76.9 $\pm$ 9.4	75.8 $\pm$ 9.7	77.3 $\pm$ 9.1	77.8 $\pm$ 8.1	76.9 $\pm$ 11.2	0.96
PA (METs/week)	3667 $\pm$ 5604	2741 $\pm$ 1522	3257 $\pm$ 1845	2262 $\pm$ 1933	6280 $\pm$ 10512	0.20
Medication use						
Antihypertensive	6 (9.8%)	1 (6%)	1 (6%)	1 (7%)	3 (20%)	-
Hormonal therapy						
Thyroxin	9 (14.5%)	3 (19%)	1 (6%)	4 (29%)	1 (7%)	-
Testosterone	1 (1.6%)	1	0	0	0	-

Antihistamine	1 (1.6%)	0	0	1 (7%)	0	-
Lipid lowering agents	10 (16%)	5 (31%)	2 (12%)	1 (7%)	2 (13%)	-
Vitamin D	3 (3%)	1 (6%)	2 (12%)	0	0	-
Aspirin	1 (1.6%)	0	0	0	1 (7%)	-
Corticosteroid inhalers	2 (3%)	0	1 (6%)	0	1 (7%)	-
No therapy	35 (56%)	10 (63%)	9 (53%)	7 (50%)	9 (60%)	-

M/F, male/female; BMI, body mass index; WC, waist circumference; FM, fat mass; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; PA, physical activity; PA, physical activity; data are expressed as mean ± standard deviation (SD). Medications are presented as n (%). P values are based on one-way analysis of variance (ANOVA), except for gender which were based on Chi square test. HN; High nitrate, MN; Medium nitrate, LN; Low nitrate, PL; Placebo.

### 3.2. Recruitment and Retention

Sixty-two participants were included in the study and randomized to one of the four intervention groups as follows: 16 participants were allocated to Group 1 (2 shots of BJ/day, every morning and evening), 17 participants to Group 2 (1 shots of BJ/day, every evening), 14 participants to Group 3 (1 shot of BJ every other evening) and 15 participants were allocated to Group 4 (Placebo, 1 shot of BJ depleted NO<sub>3</sub><sup>-</sup> every other evening) (please see [15] for further details). The overall attrition rate for the study was 19% with 12 participants dropping from the study. The highest attrition rate was found to be in the HN group with 38% of participants who enrolled to this group, followed by the MN and PL groups with 24% and 20%, respectively. No participants dropped out from LN group. Fifty participants completed the study. Figure 2 shows the flowchart of participants recruited into the feasibility study. Reasons for withdrawal from the study are summarised in Table 2.




Figure 2. Flowchart of participants recruited into the feasibility study.

Table 2. Primary reasons for withdrawal from study.

Reasons	N (%)	Specific Reasons Provided by Participants
Uncomfortable bowel movement	3 (25)	“The number of times I spent going to the toilet increased, I go to the toilet up to eight times a day, it is obvious that

		<p>something in the supplement has a certain effect on me"</p> <p>"I drank the beetroot juice (BJ), within 15 minutes I had to rush to the lavatory with diarrhoea".</p> <p>"I need to give up, BJ seems to be giving me extremely loose bowels and I have had to stop taking it"</p>
Taste and smell of BJ	3 (25)	<p>"The smell, taste and texture are all extremely unpleasant, leaving me with a feeling of nausea for a long time after taking the BJ (Sometimes hours)".</p> <p>"I am so sorry I have to pull out, because of the horrible taste of BJ, I was cheating: can't drink all of the bottle, don't want to spoil your study"</p> <p>"There is a fundamental problem in that I can't tolerate the juice. I hate the juice; the consistency makes me feel sick and it is way too sweet. Much as I love beetroot, I cannot drink this".</p>
Moving out of the area	1 (8)	<p>"I regret to say due to an enormous amount of travelling I have had to endure recently, I will have to drop out from your research scheme"</p>
Complicated study	2 (16)	<p>"Sorry, but I find it all a chore, with travelling in and out of town. Sorry I would like to exit from trial"</p>
Teeth problems	1 (8)	<p>"Unfortunately, I do think I will need to stop the study. too much sugar in the juices which are spoiling my teeth, I often have headaches after I drink them"</p>

Bereavement family	1 (8)	-
Mouthwash use	1 (8)	-

### 3.3. Compliance

#### 3.3.1. Intervention Intake

The daily log sheets used to record BJ consumption indicated excellent compliance with the intervention for the large majority of participants. Across all intervention groups, the overall compliance was more than 90%. The compliance rate was similar between groups ( $P = 0.52$ ). The compliance with intervention for each individual participant is summarised in Figure S1.

#### 3.3.2. Sample Collection at Home and Delivery by Post to the Research Centre

All participants who completed the study ( $n = 50$ ) adhered to the protocol for home collection of the biological samples during the study. Participants did not report any difficulties with posting the samples using the pre-paid delivery boxes. We expected to receive the samples within 2 days from posting and we asked participants specifically to avoid posting the samples during weekends or on public holidays. However, we experienced delays in receiving some of the samples. In total, 16 samples were delivered at least 3 days after being posted. The number of days between posting and receipt of the samples at the research centre are detailed in Figure S2. During the first month of the study, 22 boxes were received the next day after posting, 8 were received after 2 days, and 8 boxes were delivered at least 3 days after posting. During the second month of the study, 12 boxes were received the next day after posting, 13 boxes were received after 2 days, and 8 boxes were received at least 3 days after posting. Some samples were also collected from the participant's home ( $n = 5$ ), and in some cases participants took the samples directly to the research centre ( $n = 28$ ).

#### 3.3.3. Recording Dietary Intake Using Intake24


Thirty-eight (76%) participants completed all 6 dietary intake records. Of those, 3 participants reported their intakes on paper due to difficulty with accessing the software, and dietary data were then uploaded to Intake24 by a member of the research team. Twelve (24%) participants had incomplete dietary intake records due to non-adherence. Among that group, 9 participants had less than three dietary records. This finding is summarised in Figure S3.

### 3.4. Biomarkers of Nitrate Intake


#### 3.4.1. Plasma Nitrate and Nitrite Concentrations


Due to difficulty in collecting samples from one participant, data from 49 participants were included in the analysis. One-way ANOVA reveals that there was a statistically significant difference between intervention groups in the change from baseline in plasma  $\text{NO}_3^-$  concentration at 13-weeks ( $P < 0.001$ ). Compared with PL, plasma  $\text{NO}_3^-$  concentrations increased significantly after HN ( $\Delta 236 \mu\text{M/L}$ , 95% CI: 126, 346  $\mu\text{M/L}$ ,  $P < 0.001$ ) and MN ( $\Delta 111 \mu\text{M/L}$ , 95% CI: 10, 212  $\mu\text{M/L}$ ,  $P = 0.02$ ) doses. No significant differences were found between the LN and PL doses ( $\Delta 18 \mu\text{M/L}$ , 95% CI: -82, 119  $\mu\text{M/L}$ ,  $P = 0.94$ ) (Figure 3A). However, evidence for a change from baseline in plasma  $\text{NO}_2^-$  concentration was less convincing ( $P = 0.054$ ). Relative to PL, plasma  $\text{NO}_2^-$  was significantly increased only after the MN dose ( $\Delta 130 \mu\text{M/L}$ , 95% CI: 12, 248  $\mu\text{M/L}$ ,  $P = 0.02$ ). There were no significant differences in the change from baseline for plasma  $\text{NO}_2^-$  for the HN ( $P = 0.12$ ) or LN ( $P = 0.56$ ) doses compared with PL (Figure 3B).

Polynomial regression analysis revealed a significant positive linear relationship between  $\text{NO}_3^-$  dose and the change in plasma  $\text{NO}_3^-$  concentration ( $R^2 = 0.71$ ,  $P < 0.001$ ) (Figure 4A). However, there was a non-linear relationship (cubic model) between  $\text{NO}_3^-$  doses and the change from baseline in plasma  $\text{NO}_2^-$  concentration ( $R^2 = 0.24$ ,  $P = 0.006$ ) (Figure 4B).



**Figure 3.** Mean changes in plasma NO<sub>3</sub><sup>-</sup> (A) and NO<sub>2</sub><sup>-</sup> (B) concentrations of incremental doses of dietary NO<sub>3</sub><sup>-</sup> in form of BJ in older overweight and obese adults. HN (High NO<sub>3</sub><sup>-</sup>; two 70mL shots of BJ/day, morning and evening), MN (Medium NO<sub>3</sub><sup>-</sup>; 70 ml of BJ/day), LN (Low NO<sub>3</sub><sup>-</sup>; 70 mL of BJ every alternate days) and PL (placebo; 70 mL of NO<sub>3</sub><sup>-</sup> depleted BJ). Each shot of BJ contains 400 mg of NO<sub>3</sub><sup>-</sup>. The change at 13-weeks from baseline data (A and B) were analysed with one-way ANOVA. Data are expressed as mean ± standard error of the mean (SEM) (n = 49).





**Figure 4.** Relationship between changes in plasma  $\text{NO}_3^-$ ,  $\text{NO}_2^-$  and doses of  $\text{NO}_3^-$ . This figure shows the relationship between changes in plasma  $\text{NO}_3^-$  (A) and  $\text{NO}_2^-$  (B) and doses of  $\text{NO}_3^-$ . Regression lines are fitted to each distribution, (A) is linear and (B) is cubic, ( $n = 49$ ).


### 3.4.2. Salivary Nitrate and Nitrite Concentrations

There was no significant difference between and within the intervention groups in salivary  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations measured at the two baseline visits ( $P = 0.29$ ,  $P = 0.6$ , respectively), confirming that participants complied with the instruction to maintain a low  $\text{NO}_3^-$  diet before both baseline visits (Figure 5A and B). For salivary  $\text{NO}_3^-$ , repeated measures analysis showed a significant effect of time ( $P < 0.001$ ), intervention ( $P < 0.001$ ), and a significant time\*intervention interaction ( $P = 0.01$ ) (Figure 5A). There was no significant difference in salivary  $\text{NO}_3^-$  concentrations between the two end-of-study measurements within the intervention groups ( $P > 0.05$ ). One-way ANOVA revealed a statistically significant difference between intervention groups in the change from baseline in salivary  $\text{NO}_3^-$  at 13 weeks ( $P < 0.001$ ). Compared with PL, salivary  $\text{NO}_3^-$  concentration at 13 weeks significantly increased after HN and MN ( $\Delta 2.7 \mu\text{M/L}$ , 95% confidence interval (CI): 0.4, 4.9,  $P = 0.02$ ), ( $\Delta 2.9 \mu\text{M/L}$ , 95% CI: 0.8, 5.0,  $P = 0.004$ ), respectively, but there was no significant difference between LN dose and PL ( $P = 0.30$ ) (Figure 5C).


For salivary  $\text{NO}_2^-$ , a significant effect of time ( $P < 0.001$ ) and intervention ( $P < 0.001$ ), and a significant interaction term ( $P = 0.045$ ) was revealed by repeated measures analysis. Similar to salivary  $\text{NO}_3^-$ , no significant difference was detected between the two end of study measurements within the intervention groups ( $P > 0.05$ ) (Figure 5B). There was a statistically significant difference between intervention groups in the change from baseline in salivary  $\text{NO}_2^-$  at 13 weeks ( $P = 0.001$ ). Salivary  $\text{NO}_2^-$  concentration at 13 weeks increased significantly after HN and MN ( $\Delta 319 \mu\text{M/L}$ , 95% CI: 119, 520  $\mu\text{M/L}$ ,  $P = 0.001$ ), ( $\Delta 217 \mu\text{M/L}$ , 95% CI: 34, 401  $\mu\text{M/L}$ ,  $P = 0.02$ ), respectively, compared with PL (Figure 5D). No significant difference was observed between LN dose and PL ( $P = 0.43$ ).

The distinct pattern of changes in concentrations of  $\text{NO}_3^-$  and  $\text{NO}_2^-$  for the LN group becomes even clearer when data from week 4 and week 8 are combined (Figure S4A and S4B). This showed a significant difference between time points for both  $\text{NO}_3^-$  and  $\text{NO}_2^-$  ( $P = 0.003$  and  $0.002$ , respectively). Compared with baseline, salivary  $\text{NO}_3^-$  concentrations increased significantly on the 1<sup>st</sup> and 3<sup>rd</sup> day of collection (based on combined data obtained at week 4 and week 8) ( $\Delta 2.3 \text{ mM/L}$ , 95% CI: 0.5, 4.2  $\text{mM/L}$ ,  $P = 0.009$ ) and ( $\Delta 2.8 \text{ mM/L}$ ,

95% CI: 0.9, 4.6 mM/L,  $P = 0.002$ ), respectively. Similarly, salivary  $\text{NO}_2^-$  concentrations increased significantly on the 1st and 3rd days ( $\Delta 454.8 \mu\text{M/L}$ , 95% CI: 65.2, 844.5  $\mu\text{M/L}$ ,  $P = 0.02$ ) and ( $\Delta 587.7 \mu\text{M/L}$ , 95% CI: 198.0, 977.4  $\mu\text{M/L}$ ,  $P = 0.001$ ), respectively. No significant difference was found between data collected on the 2nd day, at baseline and end of the study for both salivary  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations ( $P > 0.05$ ). There was a significant non-linear relationship between  $\text{NO}_3^-$  doses and changes in salivary  $\text{NO}_3^-$  ( $R^2 = 0.35$ ,  $P = 0.002$ ) and  $\text{NO}_2^-$  ( $R^2 = 0.23$ ,  $P = 0.007$ ) concentrations (Figure 6A and B)



**Figure 5.** Salivary  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations in older overweight and obese adults. (A and B) Mean salivary  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations measured at baseline, 4 weeks, 8 weeks, and after 13-weeks for each of the intervention groups, respectively. (C and D) The mean change in salivary  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations between baseline and week 13 for each of the intervention groups, respectively. HN (High  $\text{NO}_3^-$ ; two 70mL shots of BJ/day, morning and evening), MN (Medium  $\text{NO}_3^-$ ; 70 mL of BJ/day), LN (Low  $\text{NO}_3^-$ ; 70 mL of BJ every alternate days) and PL (placebo; 70 mL of  $\text{NO}_3^-$ -depleted BJ). Each shot of BJ contains 400 mg of  $\text{NO}_3^-$ . (A and B) Data were analysed using a 2-factor repeated measures ANOVA (time\*group of intervention). (C and D) These changes of from baseline were analysed with one-way ANOVA. Data are expressed as mean  $\pm$  SEM, ( $n = 50$ ).




**Figure 6.** The relationship between the changes in salivary  $\text{NO}_3^-$  (A) and  $\text{NO}_2^-$  (B) and daily doses of  $\text{NO}_3^-$  delivered during the intervention. A cubic model was the best fit for each distribution ( $n = 50$ ).


### 3.4.3. Urinary Nitrate Concentration

There was no significant difference in urinary  $\text{NO}_3^-$  concentrations at baseline between intervention groups ( $P = 0.35$ , Figure 7A). However, there was a significant effect of time ( $P < 0.001$ ), intervention ( $P < 0.001$ ), and time\*intervention interaction for urinary  $\text{NO}_3^-$  ( $P < 0.001$ ) and one-way ANOVA revealed a statistically significant difference between intervention groups in the change from baseline in urinary  $\text{NO}_3^-$  at 13 weeks ( $P < 0.001$ ). Compared with PL, urinary  $\text{NO}_3^-$  concentration was significantly greater after HN ( $\Delta 6.5 \mu\text{M/L}$ , 95% CI: 3.8, 9.2,  $P < 0.001$ ) and MN ( $\Delta 4.3 \mu\text{M/L}$ , 95% CI: 1.8, 6.8,  $P < 0.001$ ) (Figure 7B). Figure 7A shows that urinary  $\text{NO}_3^-$  concentrations were high and stable over time with HN and MN doses whereas urinary  $\text{NO}_3^-$  concentrations were relatively unchanged in the PL group. The pattern of change in urinary  $\text{NO}_3^-$  concentration for the LN

group was similar to that for salivary NO<sub>3</sub><sup>-</sup> concentrations with a significant difference between time points ( $P = 0.001$ ). Compared with baseline, urinary NO<sub>3</sub><sup>-</sup> concentration increased significantly on the 1<sup>st</sup> and 3<sup>rd</sup> day (based on combined data obtained at week 4 and week 8) ( $\Delta 3.9$  mM/L, 95% CI: 1.5, 6.3 mM/L,  $P = 0.001$ ) and ( $\Delta 4.3$  mM/L, 95% CI: 1.9, 5.9 mM/L,  $P < 0.001$ ), respectively (Figure S5). There was a significant linear relationship between NO<sub>3</sub><sup>-</sup> dose and change from baseline in urinary NO<sub>3</sub><sup>-</sup> concentration ( $R^2 = 0.46$   $P < 0.001$ , Figure 8).



**Figure 7.** Urinary NO<sub>3</sub><sup>-</sup> concentrations in older overweight and obese adults. **(A)** Mean urinary NO<sub>3</sub><sup>-</sup> concentrations measured at baseline, 4 weeks, 8 weeks, and after 13-weeks for each of the intervention groups. **(B)** The Mean of the change in urinary NO<sub>3</sub><sup>-</sup> concentrations between baseline and week 13 for each of the intervention groups. HN (High NO<sub>3</sub><sup>-</sup>; two 70 mL shots of BJ/day, morning and evening), MN (Medium NO<sub>3</sub><sup>-</sup>; 70 mL of BJ/day), LN (Low NO<sub>3</sub><sup>-</sup>; 70 mL of BJ every alternate days) and PL (placebo; 70 mL of NO<sub>3</sub><sup>-</sup> depleted BJ). Each shot of BJ contains 400 mg of NO<sub>3</sub><sup>-</sup>. **(A)** Data were analysed using a 2-factor repeated measures ANOVA (time\*group of intervention). **(B)** These changes from baseline were analysed with one-way ANOVA. Data are expressed as mean  $\pm$  SEM, ( $n = 50$ ).




**Figure 8.** Linear relationship between the changes in urinary NO<sub>3</sub><sup>-</sup> and doses of NO<sub>3</sub><sup>-</sup> ( $n = 50$ ).

### 3.4.4. Salivary Nitrite Strips

Baseline salivary NO<sub>2</sub><sup>-</sup> concentration, measured by the strips, was similar for all intervention groups ( $P > 0.05$ ). Repeated-measure analysis showed a significant effect of time ( $P < 0.001$ ), intervention ( $P < 0.001$ ), and time\*intervention interaction ( $P < 0.001$ ).

During the intervention, the HN and MN groups showed significant elevation in salivary  $\text{NO}_2^-$  concentrations when compared with PL ( $P < 0.001$  and  $P = 0.002$ , respectively). The LN group showed a more moderate increase in salivary  $\text{NO}_2^-$  concentration ( $P = 0.05$ ) with day-to-day variation mirroring the alternate day provision of the BJ supplement (Figure 9). There was a significant correlation ( $r = 0.41$ ,  $P < 0.001$ ) between salivary  $\text{NO}_2^-$  concentration measured by the strips and that measured by ozone-based chemiluminescence (Figure S6).



**Figure 9.** Salivary  $\text{NO}_2^-$  strips readings (Berkeley). Mean salivary  $\text{NO}_2^-$  strips readings (Berkeley) measured at baseline, 4 weeks, 8 weeks, and after 13 weeks. HN (High  $\text{NO}_3^-$ ; two 70ml shots of BJ/day, morning and evening), MN (Medium  $\text{NO}_3^-$ ; 70 mL of BJ/day), LN (Low  $\text{NO}_3^-$ ; 70 mL of BJ every alternate days) and PL (placebo; 70 mL of  $\text{NO}_3^-$  depleted BJ). Each shot of BJ contains 400 mg of  $\text{NO}_3^-$ . Data were analysed using a 2-factor repeated measures ANOVA (time\*group of intervention). Data are expressed as mean  $\pm$  SEM, ( $n = 50$ ).

### 3.5. The Relationship between the Duration of Postal Delivery Time and the Concentration of $\text{NO}_2^-$ and $\text{NO}_3^-$ Saliva and Urine

A sensitivity analysis was conducted to check whether the delay in receiving some samples affected the biomarker concentrations. Overall, there was no statistically significant difference in salivary  $\text{NO}_2^-$  and  $\text{NO}_3^-$  and urinary concentrations of  $\text{NO}_3^-$  with time between posting by the participant and receipt of samples in the research centre ( $P > 0.05$ , **Figure S7**). Post hoc analysis showed a trend towards a lower salivary  $\text{NO}_2^-$ , but not salivary  $\text{NO}_3^-$  concentration, in samples received after 3 or more days compared with 2 or 1 days ( $P = 0.07$  and  $P = 0.08$ , respectively).

### 3.6. Acceptability of Dietary Intervention and Study Protocol

Completed questionnaires were returned by 52 participants. The primary reasons for participating in the study were: (1) interest in nutritional research ( $n = 25$ ) and (2) health benefits of beetroot ( $n = 18$ ). Regarding their expectations from participating to the study, the majority of participants had no obvious expectations ( $n = 28$ ) while some expected that the BJ could improve their health and wellbeing ( $n = 18$ ). Interestingly, the majority of participants ( $n = 38$ ) expressed an interest in being approached for a similar future study, whereas only 13 said that they would not participate in another similar study. The main reasons for not wishing to participate in a similar future study were (1) taste of BJ and (2) duration of the study. Other participants would not participate because of the side effects and/or the saliva collection procedure. One participant said: "We would definitely taste the product first!" In addition, almost half of the participants ( $n = 24$ ) reported that they would not join a longer study (i.e., with a duration longer than three months).

Thirty-three participants reported that they did not eat or drink BJ regularly and the most frequent reasons were the limited availability and its unpleasant taste: "I don't like beetroot at all". "I like beetroot but it's not always available and convenient to prepare". When participants were asked whether or not they would recommend BJ, the overall responses ( $n = 34$ ) were supportive and some of the key reasons are outlined below:

"I believe it provides benefits to blood circulation."

"I feel my thoughts are clearer. My focus on things is better. I even took it to Amsterdam with me!"

"It depends on research results; I would not recommend it due to the taste."

"I believe it's good for health and it has a pleasant taste!"

"I felt my memory slightly improved and my blood pressure was down."

"It's a convenient way to take the beetroot, even though the taste is odd."

"I don't feel that many people would tolerate the taste without a proven benefit!"

"It has possibly improved my blood. Even the nurse was surprised from my blood results!"

The majority of participants reported no major concerns or preferences with the consumption of BJ while others found it difficult due primarily to taste:

"I hate the taste. The only way was to hold my nose whilst drinking."

"Sometimes I had to hold my nose to gulp it down."

"The smell, the syrupy texture, the Saltiness, all not good."

"The taste made me gag."

When participants were asked if they felt any difference as a result of the BJ consumption, several participants reported that they felt some beneficial effects after the intervention:

"Maybe an increase in my concentration levels."

"My blood pressure reading has gone down, which is good."

"Memory improvement."

"Yes, I felt my cognition has improved, I am finding solutions to complicated situations!"

"I feel more alert."

"Feel like I am thinking quicker."

"I feel my memory improved."

Overall, feedback about the measurements undertaken as part of the study protocol was positive and participants found the procedures acceptable. The only exception was for use of Intake24 to record dietary intake, where the feedback was mixed. Although 31 participants did not have any difficulty using Intake24, 19 found that Intake24 was difficult and complex to complete. The main problems were that it was time consuming and participants could not find all food items that they had eaten within the platform's database.

#### 4. Discussion

Over the past decade, there has been increased investigation of the beneficial effects of dietary  $\text{NO}_3^-$  on health outcomes, including blood pressure, glucose control, insulin resistance, dyslipidemia, cognition, heart failure and peripheral arterial diseases [22–26]. However, most of these studies have been of short duration and there has been little investigation of the long-term effects of dietary  $\text{NO}_3^-$  supplementation on physiological functions, especially in older people. To the best of our knowledge, this pilot RCT is one of the longest that examined the feasibility and acceptability of supplementation with different doses of  $\text{NO}_3^-$ -rich BJ in overweight and obese older adults.

##### 4.1. Recruitment and Attrition

While the recruitment target was met, 19% of the participants did not complete the trial. Losses to follow-up are common in long-term dietary interventions and other studies have reported attrition rates of up to 21% in a 12-week intervention study [27]. The 3-

month duration of our trial appeared to impact the attrition rate, as some participants found it difficult to maintain their adherence to the intervention for such a prolonged period. Specifically, some participants ( $n = 5$ ) were able to consume BJ for up to, but not beyond, 6 weeks. Our study indicates that consumption of HN (2 BJ shots/day) may not be appropriate in long-term intervention ( $>13$  weeks) as this group showed the highest attrition rate (38%), which suggests that this dose may not be acceptable for a significant proportion of older people.

Reasons reported by participants for dropping out of the study included having adverse effects, such as gastrointestinal (GI) symptoms ( $n = 3$ ), or an unwillingness to ingest the BJ due to its taste or smell ( $n = 3$ ). However, these adverse events were reported mainly from participants in the HN groups who consumed two BJ shots per day. Mild gastrointestinal symptoms have been reported within 2–2.5 hours after ingestion of similar BJ doses (140 ml) [28,29]. This indicates that the consumption of concentrated BJ for prolonged periods may have adverse effects on gastrointestinal function in some individuals. In addition, the perceived unpleasant smell and taste of BJ is an important aspect of study design to consider in future investigations using a similar BJ product. One possible solution would be to introduce a taste session of the BJ product at the screening visit so that participants can make an informed decision on the acceptability of the product [30].

#### 4.2. Compliance with Dietary Intervention

The challenge of ensuring adequate compliance in dietary intervention studies is well known, especially when such studies take place over longer periods and in free-living settings [10,31]. Although the present study was demanding, as reported by several participants, this study demonstrated a high degree of compliance with BJ consumption (i.e.,  $>90\%$ ). This is an important indicator of the feasibility of this 13-week randomized trial. The incentive given at the end of the study, in conjunction with the support provided by the research team and the reminders sent during the trial, may have contributed to the high compliance. Only one participant had a low compliance; this participant stopped taking the BJ in the final two weeks due to GI problems.

#### 4.3. Collection of Biological Samples at Home and Transfer to the Research Centre by Post

Measuring nutritional intake biomarkers can help in monitoring and confirming compliance with dietary interventions, and several studies have used concentrations of  $\text{NO}_3^-$  and  $\text{NO}_2^-$  in biofluids as a measure of  $\text{NO}_3^-$  intake compliance in RCTs [13,32]. Thus, biological samples, including urine, saliva and salivary  $\text{NO}_2^-$  strips, were collected at home by participants during the study. Previous studies showed that requiring participants to travel to the research centre frequently to provide biological samples reduced adherence to the study protocol [33]. The number of collected samples required can become unwieldy for participants, leading to loss of follow up. These barriers can be overcome by the use of at home collection biological sample protocols [34]. The present study showed that participants had an excellent adherence in collecting biological samples at home, which indicate the acceptability of this procedure.

The process of the transportation of the samples from participants' homes to research centre may affect sample integrity in bioanalysis. The ideal approach would be to collect the samples from the participants and place them on dry ice on the day of collection, then store them within a few hours in  $-20^\circ\text{C}$  freezers. However, the delivery of the samples by mail was considered a more pragmatic and realistic approach to reduce the burden on researchers and participants. We predicted that most of the samples would be delivered to the research centre within two days, ensuring the stability of the samples. This feasibility study demonstrated that most samples were delivered within 2 days, with only a few cases taking more than 5 days. During this delay, samples were at room temperature, which could affect the concentrations of  $\text{NO}_3^-$  and  $\text{NO}_2^-$ .

However, there was little evidence that these conditions affected  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations. Our analysis indicates that salivary  $\text{NO}_3^-$  or  $\text{NO}_2^-$  concentrations were stable

for at least 48 hours following their collection for samples maintained at room temperature, whereas urinary  $\text{NO}_3^-$  concentrations were stable for longer periods (3 to 4 days) at room temperature. This suggests that both home collection of saliva and urine samples may be used, with appropriate protocols for collection and delivery times, as biomarkers of  $\text{NO}_3^-$  intake.

#### 4.4. Biomarkers of Nitrate Intake after Prolonged Beetroot Juice (BJ) Consumption

##### 4.4.1. Plasma Nitrate and Nitrite

There was a significant linear increase in plasma  $\text{NO}_3^-$  concentration with increasing dose of BJ consumed. Since the time between the last BJ dose and the blood collection was ~12–18 h, this suggests that higher consumption of BJ for a long period leads to  $\text{NO}_3^-$  accumulation in the blood due to its long half-life (5–8 h) [35]. In contrast, increasing doses of BJ did not result in a linear increase in plasma  $\text{NO}_2^-$ ; the change in plasma  $\text{NO}_2^-$  was highest with MN dose with no additional changes with the HN dose. It might be expected that the HN dose would produce the highest levels of plasma  $\text{NO}_2^-$ , mirroring the finding with plasma  $\text{NO}_3^-$ . The explanation for these different findings between plasma  $\text{NO}_2^-$  and  $\text{NO}_3^-$  is not clear, but it is possible that the conversion efficiency decreased over a long period with the highest BJ dose and this should be investigated in future studies. In the current study, plasma  $\text{NO}_3^-$  and  $\text{NO}_2^-$  concentrations were elevated ~2- and ~1.3-fold, respectively in the low  $\text{NO}_3^-$  dose group although blood collection was performed ~36 hours following the last shot of BJ. This is in agreement with Bondonno et al. (2015) [36], who found that plasma  $\text{NO}_3^-$  and  $\text{NO}_2^-$  returned to baseline concentrations after 2 days following 7 days' consumption of high  $\text{NO}_3^-$  BJ.

##### 4.4.2. Salivary Nitrate and Nitrite

Around 25% of the blood  $\text{NO}_3^-$  pool is actively taken up by the salivary glands and concentrated in saliva so that salivary  $\text{NO}_3^-$  concentrations are 10–20 times higher than plasma  $\text{NO}_3^-$  concentrations [37]. Although salivary  $\text{NO}_3^-$  concentrations were elevated throughout the study in those receiving supplemental  $\text{NO}_3^-$ , a linear dose-dependent response was not apparent and salivary concentrations of  $\text{NO}_3^-$  were similar for MN and HN groups. In further investigation of the data, we found that the relatively large increase in salivary  $\text{NO}_3^-$  concentration observed in the MN group was driven by only one participant who had a very high change value in salivary  $\text{NO}_3^-$  compared to the others. When data for that participant were removed, there was a clear linear dose-dependent response in salivary  $\text{NO}_3^-$  (Figure S8).

A proportion (~5% of ingested  $\text{NO}_3^-$ ) of salivary  $\text{NO}_3^-$  is converted to  $\text{NO}_2^-$  by the action of oral facultative microflora [38] so that the concentration of  $\text{NO}_2^-$  in saliva is dependent on both the  $\text{NO}_3^-$  in saliva and the  $\text{NO}_3^-$  reductase activity of the oral microflora. Salivary  $\text{NO}_2^-$  concentrations increased with time in those given the HN and MN doses, compared with the PL. However, we observed a marked decrease in salivary  $\text{NO}_2^-$  concentrations in the HN group at 13 weeks. A similar pattern of reduction, but to a lesser extent, was observed with the MN dose. The reason for this decrease is unclear. It is unlikely that this reduction is related to the capacity of active  $\text{NO}_3^-$  transport to the saliva, since salivary  $\text{NO}_3^-$  concentration was increased at this time (13 weeks). In addition, it is unlikely that this finding is related to the time of sample collection, which was performed ~12–18 hours following the last ingestion, or due to overnight fasting before the collection, as suggested by Blekkenhorst et al. (2018). In this study, participants were asked to follow similar instructions at home when they collected samples during the first and second months of the study, and there were marked increases in salivary  $\text{NO}_2^-$  concentration observed at these times, especially with the HN group. Recent studies have shown that dietary  $\text{NO}_3^-$  supplementation alters the oral microbiome [39,40] and increases the oral pH [40–42]. Oral  $\text{NO}_3^-$  reductase activity is highest at a pH of ~7.0 to 8.0, and falls with increasing acidity [43]. Studies to date have been of short duration and whether long-term

NO<sub>3</sub><sup>-</sup> supplementation has a different effect on the oral microbiota or on oral pH remains unknown.

In the LN group, there were very marked fluctuations in both salivary NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> concentrations when BJ was consumed on alternate days and this was even more apparent when data from week 4 and week 8 were combined. When the saliva samples were collected at ~36 hours post BJ ingestion, the salivary NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> concentrations were much lower than those collected ~12–18 hours following the last BJ ingestion. This finding indicates that, following increased NO<sub>3</sub><sup>-</sup> intake, salivary concentrations of NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> remain elevated for a relatively limited period of time (~up to 18 hours), even with prolonged intake. Thus frequent (daily) consumption of NO<sub>3</sub><sup>-</sup> is required to maintain elevated concentrations of these biomarkers.

#### 4.4.3. Salivary Nitrite Strips

In a previous study, we found that salivary NO<sub>2</sub><sup>-</sup> strips are a reliable method to detect changes in salivary NO<sub>2</sub><sup>-</sup> over a 5-hour period after a single shot of BJ [44]. The present study provided an opportunity to determine whether such strips can detect changes in salivary NO<sub>2</sub><sup>-</sup> over a long period of supplementation with different doses of NO<sub>3</sub><sup>-</sup>. We observed a significant moderate correlation between NO<sub>2</sub><sup>-</sup> concentrations measured by the strips and those estimated by chemiluminescence for samples collected 12–18 hours following BJ ingestion. Our observation of no increase in salivary NO<sub>2</sub><sup>-</sup> using the strips for samples taken 36 h after the last BJ ingestion is consistent with our observation of no significant increase in salivary NO<sub>2</sub><sup>-</sup> concentration in the same samples when assayed by chemiluminescence. In conclusion, this evidence confirms that salivary NO<sub>2</sub><sup>-</sup> strips are a useful tool for monitoring NO<sub>3</sub><sup>-</sup> intake in chronic NO<sub>3</sub><sup>-</sup> intervention studies.

#### 4.4.4. Urinary Nitrate

Approximately 70% of ingested NO<sub>3</sub><sup>-</sup> is excreted as such in the urine and it is not known how the remaining amount is excreted [45,46]. In the present study, there was a significant linear increase in urinary NO<sub>3</sub><sup>-</sup> concentration with increasing BJ consumption. In addition, over the 13 weeks of the study, urinary NO<sub>3</sub><sup>-</sup> concentration within each treatment group remained generally constant which suggests that there was no adaptation in urinary nitrate excretion following sustained exposure to higher intakes. This is consistent with results reported by Berends et al. (2019) and Jajja et al. (2015), who showed that urinary nitrate excretion remained at similar elevated levels during periods of the NO<sub>3</sub><sup>-</sup> supplementation.

The majority of ingested NO<sub>3</sub><sup>-</sup> is excreted in urine during the following 24 hours [47]. Previous studies have shown that urinary NO<sub>3</sub><sup>-</sup> concentration returned to baseline 24 hours after NO<sub>3</sub><sup>-</sup> ingestion [48,49] which is consistent with our observation that urinary NO<sub>3</sub><sup>-</sup> concentration decreased markedly when samples were collected 36 hours after BJ ingestion in the low-dose NO<sub>3</sub><sup>-</sup> group.

## 5. Conclusions

In summary, this feasibility study provided valuable information on how to overcome the challenges in recruiting and retaining older overweight/obese adults in a relatively long-term BJ supplementation study. The appropriate use of intensives and phone or email reminders served to optimise participant retention, to maximize the collection of biological samples and to ensure overall compliance with the protocol of the study. In addition, this study demonstrated the feasibility of conducting a longer-term BJ supplementation intervention (lasting 13 weeks) among older participants, which, overall, was well tolerated with no serious adverse events. However, the study indicates that the HN dose may not be acceptable to a significant proportion of older people in long-term -intervention studies. Finally, the findings from this study will help inform the design of larger

and longer studies investigating the effects of NO<sub>3</sub>-rich BJ on health outcomes in older people.

**Supplementary Materials:** The following are available online at [www.mdpi.com/2072-6643/13/3/769/s1](http://www.mdpi.com/2072-6643/13/3/769/s1), Figure S1: Compliance with the intervention, Figure S2: Distribution of number of days between samples being posted by the participants and receipt by the researcher, Figure S3: Number of dietary intake records completed by participants. Participants used Intake24 software to record their dietary intakes every two weeks during the trial, Figure S4: Mean of salivary NO<sub>3</sub><sup>-</sup> (A) and NO<sub>2</sub><sup>-</sup> (B) concentrations in LN group (low NO<sub>3</sub><sup>-</sup> dose; 70 ml of BJ every alternate days), Figure S5: Mean of urinary NO<sub>3</sub><sup>-</sup> concentrations in the LN group (low NO<sub>3</sub><sup>-</sup> dose; 70 ml of BJ every alternate days), Figure S6: Scatterplot of Pearson correlation between Berkeley salivary NO<sub>2</sub><sup>-</sup> strips readings and salivary NO<sub>2</sub><sup>-</sup> concentrations. Figure S7: Salivary NO<sub>2</sub><sup>-</sup>, NO<sub>3</sub><sup>-</sup> and urinary NO<sub>3</sub><sup>-</sup> (C) concentrations. Feedback questionnaire. Supplemental methods. Figure S8: Mean of salivary NO<sub>3</sub><sup>-</sup> concentrations after removing data from one participant.

**Author Contributions:** Conceptualization, A.M.B, M.S. and J.C.M.; methodology, A.M.B.; formal analysis, A.M.B, M.S. and J.C.M.; investigation, A.M.B.; resources, M.S and J.C.M.; data curation, A.M.B, M.S. and J.C.M.; writing—original draft preparation, A.M.B.; writing—review and editing, J.C.M., G.M.O., M.S., O.S., D.O, I.M., E.W.,D.K., E.S., E.O., W.F., A.A.K., N.M., C.K.,S.R.; visualization, A.M.B.; supervision, M.S, J.C.M and G.M.O.; project administration, M.S and J.C.M.; funding acquisition, M.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by Newcastle University core budget.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Faculty of Medical Sciences, Newcastle University (1503/4477/2018).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy concerns.

**Acknowledgments:** We would like to thank the study participants and staff.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Niccoli, T.; Partridge, L. Ageing as a risk factor for disease. *Curr. Biol.* **2012**, *22*, R741–R752.
2. Storey, A. Living Longer—How our Population Is Changing and Why It Matters; Office for National Statistics, UK, 2018.
3. Malcomson, F.C.; Mathers, J.C. Nutrition and ageing. In *Biochemistry and Cell Biology of Ageing: Part I Biomedical Science*; Springer: Berlin/Heidelberg, Germany, 2018; pp. 373–424.
4. Ridda, I.; Macintyre, C.; Lindley, R.; Tan, T. Difficulties in recruiting older people in clinical trials: An examination of barriers and solutions. *Vaccine* **2010**, *28*, 901–906.
5. Florence, C.S.; Bergen, G.; Atherly, A.; Burns, E.; Stevens, J.; Drake, C. Medical costs of fatal and nonfatal falls in older adults. *J. Am. Geriatr. Soc.* **2018**, *66*, 693–698.
6. Cherubini, A.; Gasperini, B. How to Increase the Participation of Older Subjects in Research: Good Practices and more Evidence Are Needed! Oxford University Press: Oxford, UK, 2017.
7. Knechel, N.A. The challenges of enrolling older adults into intervention studies. *Yale J. Biol. Med.* **2013**, *86*, 41.
8. Cusack, S.; O'toole, P.W. Challenges and implications for biomedical research and intervention studies in older populations: Insights from the ELDERMET study. *Gerontology* **2013**, *59*, 114–121.
9. Akmatov, M.K.; Jentsch, L.; Riese, P.; May, M.; Ahmed, M.; Werner, D.; Rosel, A.; Prokein, J.; Bernermann, I.; Klopp, N. et al. Motivations for (non) participation in population-based health studies among the elderly—comparison of participants and non-participants of a prospective study on influenza vaccination. *BMC Med. Res. Methodol.* **2017**, *17*, 18.
10. Crichton, G.E.; Howe, P.R.; Buckley, J.D.; Coates, A.M.; Murphy, K.J.; Bryan, J. Long-term dietary intervention trials: Critical issues and challenges. *Trials* **2012**, *13*, 111.
11. Toda, N.; Okamura, T. Obesity impairs vasodilatation and blood flow increase mediated by endothelial nitric oxide: An overview. *J. Clin. Pharmacol.* **2013**, *53*, 1228–1239.
12. Raubenheimer, K.; Kickey, D.; Leveritt, M.; Fassett, R.; De Zavallos Munoz, J.; Allen, J.D.; Briskey, D.; Parker, T.J.; Kerr, G.; Peake, J.M. et al. Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study. *Nutrients* **2017**, *9*, 1270.

13. Jajja, A.; Sutyarjoko, A.; Lara, J.; Rennie, K.; Brandt, K.; Qadir, O.; Seirvo, M. Beetroot supplementation lowers daily systolic blood pressure in older, overweight subjects. *Nutr. Res.* **2014**, *34*, 868–875.
14. Vanhatalo, A.; Kelly, J.; Winyard, P.G.; Fulford, J. Jones, A.M. Dietary Nitrate Reduces Blood Pressure and Improves Walking Economy and Cognitive Function in Older People: 910 Board# 226 June 1, 330 PM–500 PM. *Med. Sci. Sports Exerc.* **2016**, *48*, 257.
15. Babateen, A.M.; Rubele, S.; Shannon, O.M.; Okello, E.; Smith, E.; McMahon, N.; O'Brien, G.M.; Wightman, E.; Kennedy, D.; Mathers, J.C. et al. Protocol and recruitment results from a 13-week randomized controlled trial comparing the effects of different doses of nitrate-rich beetroot juice on cognition, cerebral blood flow and peripheral vascular function in overweight and obese older people. *Contemp. Clin. Trials Commun.* **2020**, *18*, 100571.
16. Craig, C.L.; Marshall, A.L.; Sjostrom, M.; Bauman, A.E.; Booth, M.L.; Ainsworth, B.E.; Pratt, M.; Ekelun, U.; Yangve, A.; Sallis, J.F. et al. International physical activity questionnaire: 12-country reliability and validity. *Med. Sci. Sports Exerc.* **2003**, *35*, 1381–1395.
17. Kapil, V.; Haydar, S.M.; Pearl, V.; Lundberg, J.O.; Weitzberg, E.; Ahluwalia, A. Physiological role for nitrate-reducing oral bacteria in blood pressure control. *Free Radical Biology and Medicine*, **2013**, *55*, 93–100.
18. Foster, E.; Hawkins, A.; Delve, J.; Adamson, A.J. Reducing the cost of dietary assessment: Self-Completed Recall and Analysis of Nutrition for use with children (SCRAN 24). *J. Hum. Nutr. Diet.* **2014**, *27*, 26–35.
19. Shannon, O.M.; Duckworth, L.; Barlow, M.J.; Woods, D.; Lara, J.; Seirvo, M.; O'Hara, J.P. Dietary nitrate supplementation enhances high-intensity running performance in moderate normobaric hypoxia, independent of aerobic fitness. *Nitric Oxide* **2016**, *59*, 63–70.
20. Justice, J.N.; Johnson, L.C.; DeVan, A.E.; Cruickshank-Quinn, C.; Reisdorph, N.; Bassett, C.J.; Evans, T.D.; Brooke, F.A.; Bryan, N.; Chonchol, M.B. et al. Improved motor and cognitive performance with sodium nitrite supplementation is related to small metabolite signatures: A pilot trial in middle-aged and older adults. *Aging (Albany NY)* **2015**, *7*, 1004.
21. Whitehead, A.L.; Julious, S.A.; Cooper, C.L.; Campbell, M.J. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat. Methods Med. Res.* **2016**, *25*, 1057–1073.
22. Kelly, J.; Fulford, J.; Vanhatalo, A.; Blackwell, J.R.; French, O.; Bailey, S.J.; Gilchrist, M.; Winyard, P.G.; Jones, A.M. Effects of short-term dietary nitrate supplementation on blood pressure, O<sub>2</sub> uptake kinetics, and muscle and cognitive function in older adults. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2013**, *304*, R73–R83.
23. d'El-Rei, J.; Cunha, A.; Trindade, M.; Neves, M.F. Beneficial effects of dietary nitrate on endothelial function and blood pressure levels. *Int. J. Hypertens.* **2016**, *2016*, doi:10.1155/2016/6791519.
24. Khalifi, S.; Rahimpour, A.; Jeddi, S.; Ghanbari, M.; Kazerouni, F.; Ghasemi, A. Dietary nitrate improves glucose tolerance and lipid profile in an animal model of hyperglycemia. *Nitric Oxide* **2015**, *44*, 24–30.
25. Presley, T.D.; Morgan, A.R.; Bechtold, E.; Clodfelter, W.; Dove, R.W.; Jennings, J.M.; Kraft, R.A.; King, S.B.; Laurienti, P.J.; Rejeski, W.J. et al. Acute effect of a high nitrate diet on brain perfusion in older adults. *Nitric Oxide* **2011**, *24*, 34–42.
26. Allen, J.D.; Giordano, T.; Kevil, C.G. Nitrite and nitric oxide metabolism in peripheral artery disease. *Nitric Oxide* **2012**, *26*, 217–222.
27. Sudha, M.R.; Ahire, J.J.; Tripathi, A.; Nanal, S. Effect of multi-strain probiotic (UB0316) in weight management in overweight/obese adults: A 12-week double blind, randomised, placebo-controlled study. *Benef. Microbes* **2019**, *10*, 855–866.
28. Jonvik, K.L.; Willem Van Dijk, J.; Senden, J.M.; van Loon, L.J.; Verdijk, L.B. The effect of beetroot juice supplementation on dynamic apnea and intermittent sprint performance in elite female water polo players. *Int. J. Sport Nutr. Exerc. Metab.* **2018**, *28*, 468–473.
29. Jonvik, K.L.; Nyakayiru, J.; Van Dijk, J.W.; Maase, K.; Ballak, S.B.; Senden, J.M.; Van Loon, L.J.; Verdijk, L.B. Repeated-sprint performance and plasma responses following beetroot juice supplementation do not differ between recreational, competitive and elite sprint athletes. *Eur. J. Sport Sci.* **2018**, *18*, 524–533.
30. James, P.E.; Willis, G.; Allen, J.D.; Winyard, P.G.; Jones, A.M. Nitrate pharmacokinetics: Taking note of the difference. *Nitric Oxide* **2015**, *48*, 44–50.
31. Desroches, S.; Lapinte, A.; Ratte, S.; Gravel, K.; Legare, F.; Turcotte, S. Interventions to enhance adherence to dietary advice for preventing and managing chronic diseases in adults. *Cochrane Database Syst. Rev.* **2013**, *28*, CD008722.
32. Blekkenhorst, L.C.; Lewis, J.; Prince, R.L.; Devine, A.; Bondonno, N.; Bondonno, C.; Wood, L.; Puddey, L.B.; Ward, N.C.; Croft, K.D. et al. Nitrate-rich vegetables do not lower blood pressure in individuals with mildly elevated blood pressure: A 4-wk randomized controlled crossover trial. *Am. J. Clin. Nutr.* **2018**, *107*, 894–908.
33. Rockett, J.C.; Buck, G.M.; Lynch, C.D.; Perreault, S.D. The value of home-based collection of biospecimens in reproductive epidemiology. *Environ. Health Perspect.* **2004**, *112*, 94–104.
34. Cox, K.J.; Stanford, J.B.; Blackburn, B.E.; Porucznik, C.A. Compliance with daily, home-based collection of urinary biospecimens in a prospective, preconception cohort. *Environ. Epidemiol. (Phila. Pa.)* **2019**, *3*, e050.
35. Ma, L.; Hu, L.; Feng, X.; Wang, S. Nitrate and nitrite in health and disease. *Aging Dis.* **2018**, *9*, 938.
36. Bondonno, C.; Liu, A.H.; Croft, K.D.; Ward, N.C.; Puddey, I.B.; Woodman, R.J.; Hodgson, J.M. Short-term effects of a high nitrate diet on nitrate metabolism in healthy individuals. *Nutrients* **2015**, *7*, 1906–1915.
37. Lundberg, J.O.; Weitzberg, E. NO-synthase independent NO generation in mammals. *Biochem. Biophys. Res. Commun.* **2010**, *396*, 39–45.

38. Doel, J.J.; Benjamin, N.; Hector, M.P.; Rogers, M.; Allaker, R.P. Evaluation of bacterial nitrate reduction in the human oral cavity. *Eur. J. Oral Sci.* **2005**, *113*, 14–19.
39. Burleigh, M.; Liddle, L.; Muggerridge, D.J.; Monaghan, C.; Sculthorpe, N.; Butcher, J.; Henriquez, F.; Easton, C. Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose. *Nitric Oxide Biol. Chem.* **2019**, *89*, 54–63.
40. Vanhatalo, A.; Blackwell, J.R.; L'Heureux, J.E.; William, D.W.; Smith, A.; Van der Giezen, M.; Winyard, P.G.; Jones, A.M. Nitrate-responsive oral microbiome modulates nitric oxide homeostasis and blood pressure in humans. *Free Radic. Biol. Med.* **2018**, *124*, 21–30.
41. Li, H.; Thompson, I.; Carter, P.; Whiteley, A.; Bailey, M.; Leifert, C.; Killham, K. Salivary nitrate—an ecological factor in reducing oral acidity. *Oral Microbiol. Immunol.* **2007**, *22*, 67–71.
42. Hohensinn, B.; Haselgrubler, R.; Muller, U.; Stanlbauer, V.; Lanzerstorfer, P.; Lirk, G.; Hoglinger, O.; Weghuber, J. Sustaining elevated levels of nitrite in the oral cavity through consumption of nitrate-rich beetroot juice in young healthy adults reduces salivary pH. *Nitric Oxide* **2016**, *60*, 10–15.
43. Bojić, D.V.; Bojić, A.L.; Perović, J.M. The effects of dietary nitrate, pH and temperature on nitrate reduction in the human oral cavity. *Facta Univ. Ser. Phys. Chem. Technol.* **2004**, *3*, 53–60.
44. Babateen, A.M.; Shannon, O.M.; Mathers, J.C.; Siervo, M. Validity and reliability of test strips for the measurement of salivary nitrite concentration with and without the use of mouthwash in healthy adults. *Nitric Oxide* **2019**, *91*, 15–22.
45. Wagner, D.A.; Schultz, D.S.; Deen, W.M.; Young, V.R.; Tennenbaum, S.R. Metabolic fate of an oral dose of <sup>15</sup>N-labeled nitrate in humans: Effect of diet supplementation with ascorbic acid. *Cancer Res.* **1983**, *43*, 1921–1925.
46. Schultz, D.S.; Deen, W.M.; Karel, S.F.; Wagner, D.A.; Tennenbaum, S.R. Pharmacokinetics of nitrate in humans: Role of gastrointestinal absorption and metabolism. *Carcinogenesis* **1985**, *6*, 847–852.
47. Berends, J.E.; Van den Berg, L.M.; Guggeism M.A.; Henckens, N.F.; Hossein, I.J.; deJoode, M.E.; Zamani, H.; van Pelt, K.A.; Beelen, N.A.; Kuhnle, G. et al. Consumption of Nitrate-Rich Beetroot Juice with or without Vitamin C Supplementation Increases the Excretion of Urinary Nitrate, Nitrite, and N-nitroso Compounds in Humans. *Int. J. Mol. Sci.* **2019**, *20*, 2277.
48. Leach, S.; Packer, P.; Hill, M. *Salivary and Urinary Nitrate as Measures of Nitrate Intake*; Portland Press Limited: Biochem Soc Trans: London, UK, 1987.
49. Bartholomew, B.; Hill, M. The pharmacology of dietary nitrate and the origin of urinary nitrate. *Food Chem. Toxicol.* **1984**, *22*, 789–795.